Dipeptidyl peptidase-4 dysregulation and inflammatory cytokines as dual biomarkers in ulcerative colitis ‒ a case-control study
DOI:
https://doi.org/10.15584/ejcem.2025.4.1Keywords:
dipeptidyl peptidase-4, inflammatory bowel disease, ulcerative colitisAbstract
Introduction and aim. Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) characterized by immune dysregulation and mucosal inflammation. Current UC biomarkers lack specificity, underscoring the need for novel diagnostic tools. Dipeptidyl peptidase-4 (DPP-4), a serine protease implicated in immune modulation and inflammation, and interleukin-7 (IL-7), a cytokine linked to mucosal immune dysregulation, may serve as dual biomarkers. This study aimed to evaluate the diagnostic utility of serum levels of DPP-4, C-reactive protein (CRP), and IL-7 to differentiate UC patients with UC from healthy individuals.
Material and methods. This research conducted a case-control study involving 130 individuals, 65 diagnosed with UC and 65 apparently healthy individuals serving as the control group. Blood samples were obtained to measure DPP-4, IL-7, insulin and C-reactive protein levels.
Results. The study demonstrated a significantly higher level of inflammatory markers compared to the healthy controls with a significantly higher CRP (23.38±17.76 vs. 2.38±0.89 mg/dL, p<0.001) and IL-7 concentrations (62.39±19.7 vs. 22.86±4.73 ng/L, p<0.001). and lower level of DPP-4 activity (1.33±0.19 vs. 2.37±0.35 U/L, p<0.001). ROC curve analysis revealed the excellent diagnostic performance of DPP-4 and IL-7 in identifying UC.
Conclusion. Reduced serum DPP-4 levels and elevated levels of inflammatory markers (CRP and IL-7) highlight their utility as dual biomarkers for the diagnosis and monitoring of UC disease. DPP-4 expression is inversely correlated with inflammation. These biomarkers demonstrate diagnostic potential for UC; however, longitudinal studies are needed to assess their role in monitoring disease progression and response to treatment.
Downloads
References
Ashton JJ, Mark Beattie R. Inflammatory bowel disease: recent developments. Arch Dis Child. 2024;109(5):370-376. doi: 10.1136/archdischild-2023-325668
Liu T, Han L, Tilley M, et al. Distinct clinical phenotypes for Crohn’s disease derived from patient surveys. BMC Gastroenterol. 2021;21(1):160. doi: 10.1186/s12876-021-01740-6
Nasrullah AK, Shaker Al-Joda BM, Aljumaily HS. Study of the Elevation of Galectin-3 Level in Plasma Patients with Inflammatory Bowel Disease in Babylon Province. Med J Babylon. 2025;22(1):93-97. doi: 10.4103/MJBL.MJBL_271_23
Choi YS, Kim JK, Kim WJ. Clinical characteristics and prognosis of patients with ulcerative colitis that shows rectal sparing at initial diagnosis. World J Gastrointest Endosc. 2021;13(9):407-415. doi: 10.4253/wjge.v13.i9.407
Amerikanou C, Karavoltsos S, Gioxari A, et al. Clinical and inflammatory biomarkers of inflammatory bowel diseases are linked to plasma trace elements and toxic metals; new insights into an old concept. Front Nutr. 2022;9:997356. doi: 10.3389/fnut.2022.997356
Nasser SAAJ, Radi SJ, Abd Al-Jabbar AJ. Ulcerative Colitis: Diagnosis, Treatment, and Overall Management of Adult Patients. Curr Clin Med Educ. 2024;2(5):175-194.
Le Berre C, Honap S, Peyrin-Biroulet L. Ulcerative colitis. Lancet (London, England). 2023;402(10401):571-584. doi: 10.1016/S0140-6736(23)00966-2
Coward S, Benchimol EI, Kuenzig ME, et al. The 2023 Impact of Inflammatory Bowel Disease in Canada: Epidemiology of IBD. J Can Assoc Gastroenterol. 2023;6(2):S9-S15. doi: 10.1093/jcag/gwad004
Caron B, Honap S, Peyrin-Biroulet L. Epidemiology of Inflammatory Bowel Disease across the Ages in the Era of Advanced Therapies. J Crohns Colitis. 2024;18(2):ii3-ii15. doi: 10.1093/ecco-jcc/jjae082
Chen D, Tang TX, Deng H, Yang XP, Tang ZH. Interleukin-7 Biology and Its Effects on Immune Cells: Mediator of Generation, Differentiation, Survival, and Homeostasis. Front Immunol. 2021;12:747324. doi: 10.3389/fimmu.2021.747324.
Gao J, Zhao L, Wan YY, Zhu B. Mechanism of Action of IL-7 and Its Potential Applications and Limitations in Cancer Immunotherapy. Int J Mol Sci. 2015;16(5):10267-10280. doi: 10.3390/ijms160510267
Korolkova OY, Myers JN, Pellom ST, Wang L, M’koma AE. Characterization of serum cytokine profile in predominantly colonic inflammatory bowel disease to delineate ulcerative and Crohn’s colitides. Clin Med Insights Gastroenterol. 2015;8. doi: 10.4137/CGast-S20612.
Nakase H, Sato N, Mizuno N, Ikawa Y. The influence of cytokines on the complex pathology of ulcerative colitis. Autoimmun Rev. 2022;21(3):103017. doi: 10.1016/j.autrev.2021.103017.
Belarif L, Danger R, Kermarrec L, et al. IL-7 receptor influences anti-TNF responsiveness and T cell gut homing in inflammatory bowel disease. J Clin Invest. 2019;129(5):1910-1925. doi: 10.1172/JCI121668
Qian XK, Zhang J, Li XD, Song PF, Zou LW. Research progress on dipeptidyl peptidase family: Structure, function and xenobiotic metabolism. Curr Med Chem. 2022;29(12):2167-2188.doi: 10.2174/0929867328666210915103431.
Ohm B, Moneke I, Jungraithmayr W. Targeting cluster of differentiation 26/dipeptidyl peptidase 4 (CD26/DPP4) in organ fibrosis. Br J Pharmacol. 2023;180(22):2846-2861.doi: 10.1111/bph.15967.
Chitadze G, Wehkamp U, Janssen O, Brüggemann M, Lettau M. The serine protease CD26/DPP4 in non-transformed and malignant T Cells. Cancers (Basel). 2021;13(23):5947.doi.org/10.3390/cancers 13235947.
Barchetta I, Cimini FA, Dule S, Cavallo MG. Dipeptidyl peptidase 4 (DPP4) as A novel adipokine: role in metabolism and fat homeostasis. Biomedicines. 2022;10(9):2306.doi: 10.3390.biomedicines10092306.
Kawakita E, Koya D, Kanasaki K. CD26/DPP-4: type 2 diabetes drug target with potential influence on cancer biology. Cancers (Basel). 2021;13(9):2191.doi: 10.3390/cancera13092191.
Liao HJ, Tzen JTC. The Potential Role of Cyclopeptides from Pseudostellaria heterophylla, Linum usitatissimum and Drymaria diandra, and Peptides Derived from Heterophyllin B as Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes: An In Silico Study. Metabolites. 2022;12(5):387.doi: 10.3390/metabo1.
Ou X, O’Leary HA, Broxmeyer HE. Implications of DPP4 modification of proteins that regulate stem/progenitor and more mature cell types. Blood. 2013;122(2):161-169. doi: 10.1182/blood-2013-02-487470
Trzaskalski NA, Fadzeyeva E, Mulvihill EE. Dipeptidyl Peptidase-4 at the Interface Between Inflammation and Metabolism. Clin Med Insights Endocrinol Diabetes. 2020;13. doi: 10.1177/1179551420912972
Duan L, Rao X, Braunstein Z, Toomey AC, Zhong J. Role of incretin axis in inflammatory bowel disease. Front Immunol. 2017;8:1734. doi: 10.3389/fimmu.2017.01734
Neuman MG, Nanau RM. Inflammatory bowel disease: Role of diet, microbiota, life style. Transl Res. 2012;160(1):29-44. doi: 10.1016/j.trsl.2011.09.001
Henriksen M, Jahnsen J, Lygren I, et al. C-reactive protein: A predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut. 2008;57(11):1518-1523. doi: 10.1136/gut.2007.146357
Sakurai T, Saruta M. Positioning and Usefulness of Biomarkers in Inflammatory Bowel Disease. Digestion. 2023;104(1):30-41. doi: 10.1159/000527846
Aebisher D, Bartusik-Aebisher D, Przygórzewska A, Oleś P, Woźnicki P, Kawczyk-Krupka A. Key Interleukins in Inflammatory Bowel Disease-A Review of Recent Studies. Int J Mol Sci. 2024;26(1):121. doi: 10.3390/ijms26010121.
Barata JT, Durum SK, Seddon B. Flip the coin: IL-7 and IL-7R in health and disease. Nat Immunol. 2019;20(12):1584-1593.doi: 10.1038/s41590-019-0479-x.
Belarif L, Danger R, Daguin V, et al. Interleukin-7 receptor pathway controls human T cell homing to the gut and predicts response to anti-TNFα therapy in IBD. Journal of Immunology. 2018;200(1):42.1. doi: 10.1172/JCI121668.
Jaenisch SE, Abbott CA, Gorrell MD, Bampton P, Butler RN, Yazbeck R. Circulating Dipeptidyl Peptidase Activity Is a Potential Biomarker for Inflammatory Bowel Disease. Clin Transl Gastroenterol. 2022;13(1):E00452. doi: 10.14309/ctg.0000000000000452
Radel JA, Pender DN, Shah SA. Dipeptidyl peptidase-4 inhibitors and inflammatory bowel disease risk: a meta-analysis. Ann Pharmacother. 2019;53(7):697-704. doi: 10.1177/1060028019830844
Rahim K, Shan M, Ul Haq I, et al. Revolutionizing Treatment Strategies for Autoimmune and Inflammatory Disorders: The Impact of Dipeptidyl-Peptidase 4 Inhibitors. J Inflamm Res. 2024:1897-1917. doi: 10.2147/JIR.S442106.
Li G, Crowley MJ, Tang H, Yang JY, Sandler RS, Wang T. Dipeptidyl peptidase 4 inhibitors and risk of inflammatory bowel disease among patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Care. 2019;42(7):e119-e121. doi: 10.2337/dc19-0402.
Perry C, Kapur N, Barrett TA. DPP-4 as a Novel Biomarker for Inflammatory Bowel Disease : Is It Ready for Clinical Use ? 2020;26(11):1720-1721. doi: 10.1093/ibd/izz320
Pinto-Lopes P, Afonso J, Pinto-Lopes R, et al. Serum dipeptidyl peptidase 4: a predictor of disease activity and prognosis in inflammatory bowel disease. Inflamm Bowel Dis. 2020;26(11):1707-1719. doi: 10.1093/ibd.izaa001.
Pinto-Lopes P, Melo F, Afonso J, et al. Fecal dipeptidyl peptidase-4: An emergent biomarker in inflammatory bowel disease. Clin Transl Gastroenterol. 2021;12(3):e00320. doi: 10.14309/crg.0000000000000320.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
